Nurix Therapeutics Announces $55 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Berenberg Reiterates Buy Rating on Nurix (NRIX) Following Earnings, Offers Comments on NX-2127
July 8, 2022 10:43 AM EDTBerenberg analyst Zhiqiang Shu reiterated a Buy rating and $48.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Lead program NX-2127 has moved to a Phase 1b dose expansion study. Reported at the R&D day on May 26, NX-2127, a BTK inhibitor with iMiD activity, led to deep and sustained degradation of BTK. Recall, among 13... More
